The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the "early" prepolycythemic phase of polycythemia vera and essential thrombocythemia.
暂无分享,去创建一个
A. Zanella | S. Bosari | G. Coggi | P. Bianchi | U. Gianelli | A. Moro | E. Fermo | A. Iurlo | G. L. Deliliers | C. Vener | F. Radaelli | D. Graziani
[1] C. Bloomfield,et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.
[2] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[3] P. Campbell,et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. , 2006, Blood.
[4] J. Thiele,et al. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. , 2006, Seminars in thrombosis and hemostasis.
[5] Alessia Moro,et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoieticbone marrow histology , 2006, Leukemia & lymphoma.
[6] R. Levine,et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. , 2005, Blood.
[7] M. Stratton,et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. , 2005, Blood.
[8] P. Guglielmelli,et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia , 2005, Leukemia.
[9] V. Diehl,et al. Initial (Latent) Polycythemia vera with Thrombocytosis Mimicking Essential Thrombocythemia , 2005, Acta Haematologica.
[10] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[11] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[12] H. Kreipe,et al. The polycythaemia rubra vera‐1 gene is constitutively expressed by bone marrow cells and does not discriminate polycythaemia vera from reactive and other chronic myeloproliferative disorders , 2003, British journal of haematology.
[13] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[14] J. Jelinek,et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. , 2003, Blood.
[15] J. Spivak. Polycythemia vera: myths, mechanisms, and management. , 2002, Blood.
[16] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[17] M. Lübbert,et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. , 2000, Blood.
[18] E. Ikkala,et al. Development of erythrocytosis in the course of essential thrombocythemia , 1999, Annals of Hematology.
[19] S. Bilgrami,et al. Polycythemia rubra vera. , 1995, Seminars in oncology.
[20] C. Reid,et al. The significance of endogenous erythroid colonies (EEC) in haematological disorders. , 1987, Blood reviews.
[21] S. Schwartz. Myeloproliferative Disorders , 1975, Annals of surgery.
[22] L S KAPLOW,et al. Cytochemistry of leukocyte alkaline phosphatase. Use of complex naphthol as phosphates in azo dyecoupling technics. , 1963, American journal of clinical pathology.
[23] R. McClure,et al. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders , 2006, Leukemia.
[24] J. Thiele,et al. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). , 2005, Histology and histopathology.
[25] A. Tefferi,et al. Neutrophil polycythemia rubra vera-1 expression in classic and atypical myeloproliferative disorders and laboratory correlates. , 2005, Haematologica.
[26] F. Girodon,et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. , 2004, Haematologica.
[27] Ada Maria Florena,et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. , 2004, Haematologica.
[28] Cdm Fletcher,et al. World Health Organization Classification of Tumours , 2002 .
[29] S. Murphy. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. , 1999, Seminars in hematology.
[30] L. Shih,et al. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. , 1994, Blood.
[31] C. L. Conley. Polycythemia vera. , 1990, JAMA.